Genetics of community-acquired pneumonia

被引:12
|
作者
Wunderink, RG
Waterer, GW
机构
[1] Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA
[2] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia
[3] Royal Perth Hosp, Perth, WA, Australia
关键词
genetics; community-acquired pneumonia; polymorphism; tumor necrosis factor; lymphotoxin alpha;
D O I
10.1055/s-2005-925522
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The variable clinical presentation of community-acquired pneumonia (CAP) suggests a genetic predisposition. Specific mutations or polymorphisms in host response genes such as pattern recognition molecules (PRMs), inflammatory molecules, and the coagulation system are likely to play a role in this variable response to CAP. Mannose-binding lectin polymorphisms appear to play a more dominant role in CAP than other PRMs, such as the Toll-like receptors (TLRs). The role of tumor necrosis factor (TNF) and lymphotoxin alpha (LTA) polymorphisms remain unclear despite extensive study whereas interleukin (IL)-10 and IL-1 receptor antagonist polymorphisms appear to play an important role in the anti-inflammatory response. Coagulation gene polymorphisms are likely important as well. The real value of these genetic studies in CAP and other severe infections will be when the management of an individual patient can be optimized by therapy based on the individual's genotype for molecules important in outcome.
引用
收藏
页码:553 / 562
页数:10
相关论文
共 50 条
  • [31] A comparison between time to clinical stability in community-acquired aspiration pneumonia and community-acquired pneumonia
    Jaoude, Philippe
    Badlam, Jessica
    Anandam, Anil
    El-Solh, Ali A.
    INTERNAL AND EMERGENCY MEDICINE, 2014, 9 (02) : 143 - 150
  • [32] A comparison between time to clinical stability in community-acquired aspiration pneumonia and community-acquired pneumonia
    Philippe Jaoude
    Jessica Badlam
    Anil Anandam
    Ali A. El-Solh
    Internal and Emergency Medicine, 2014, 9 : 143 - 150
  • [33] Community-acquired Pneumonia: A Global Perspective
    Waterer, Grant W.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 37 (06) : 799 - 805
  • [34] Community-acquired pneumonia as an emergency condition
    Cilloniz, Catia
    Dominedo, Cristina
    Garcia-Vidal, Carolina
    Torres, Antoni
    CURRENT OPINION IN CRITICAL CARE, 2018, 24 (06) : 531 - 539
  • [35] The burden of community-acquired pneumonia in Spain
    Monge, V
    San-Martín, M
    González, A
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2001, 11 (04) : 362 - 364
  • [36] Corticosteroids for community-acquired bacterial pneumonia
    Kalantari, Hossein
    Hassen, Getaw Worku
    ACADEMIC EMERGENCY MEDICINE, 2025, 32 (02) : 176 - 178
  • [37] Community-acquired pneumonia. A review
    Acar, Ali
    Oncul, Oral
    KLIMIK JOURNAL, 2007, 20 (01) : 3 - 16
  • [38] Doxycycline to Treat Community-acquired Pneumonia
    Musher, Daniel M.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (04) : 692 - 693
  • [39] Community-acquired Acinetobacter baumannii pneumonia
    Bachoumas, K.
    Lebert, C.
    Lacherade, J. C.
    Reignier, J.
    MEDECINE ET MALADIES INFECTIEUSES, 2015, 45 (08): : 337 - 339
  • [40] Pharmacotherapy for community-acquired pneumonia in the elderly
    Viasus, Diego
    Nunez-Ramos, Jose A.
    Viloria, Samir A.
    Carratala, Jordi
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (10) : 957 - 964